Analyst Says Pharma Co. Has No True Competitor
Source: Andrew Tsai (04/19/2024)
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.
read more >
LA Biotech's Lower Revenue Will Be Short Lived
Source: Dr. Jonathan Aschoff (04/17/2024)
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.
read more >
Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out
Source: Streetwise Reports (04/08/2024)
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.
read more >
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Source: Streetwise Reports (03/27/2024)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
read more >
Biotech Co.'s Target Price Significantly Higher Than Current
Source: Dr. Jonathan Aschoff (03/19/2024)
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
read more >